Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 7Phase 3 6Phase 1/2 5Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomatitis 1Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Fibroblast Growth Factor 7 × Clear all
NCT00393822 2014-07-15

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

Amgen

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡